GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Takeda Pharmaceutical Co Ltd (NYSE:TAK) » Definitions » Cash Flow from Financing

Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Cash Flow from Financing : $-2,428 Mil (TTM As of Mar. 2024)


View and export this data going back to 2010. Start your Free Trial

What is Takeda Pharmaceutical Co Cash Flow from Financing?

Cash from financing is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders.

For the three months ended in Mar. 2024, Takeda Pharmaceutical Co paid $0 Mil more to buy back shares than it received from issuing new shares. It spent $95 Mil paying down its debt. It paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares. It spent $61 Mil paying cash dividends to shareholders. It spent $232 Mil on other financial activities. In all, Takeda Pharmaceutical Co spent $389 Mil on financial activities for the three months ended in Mar. 2024.


Takeda Pharmaceutical Co Cash Flow from Financing Historical Data

The historical data trend for Takeda Pharmaceutical Co's Cash Flow from Financing can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Takeda Pharmaceutical Co Cash Flow from Financing Chart

Takeda Pharmaceutical Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cash Flow from Financing
Get a 7-Day Free Trial Premium Member Only Premium Member Only -9,336.29 -10,012.54 -9,025.88 -5,305.44 -2,365.63

Takeda Pharmaceutical Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Flow from Financing Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -49.38 -408.74 -951.37 -678.98 -388.62

Takeda Pharmaceutical Co Cash Flow from Financing Calculation

This is the cash generated/spent from financial activities such as share issuance (buy back), debt issuance (repayment), and dividends paid to preferred and common stockholders. In the calculation of free cash flow, cash from financing is not calculated because it is not related to operating activities.

Takeda Pharmaceutical Co's Cash from Financing for the fiscal year that ended in Mar. 2024 is calculated as:

Takeda Pharmaceutical Co's Cash from Financing for the quarter that ended in Mar. 2024 is:


Cash Flow from Financing for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2,428 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Takeda Pharmaceutical Co  (NYSE:TAK) Cash Flow from Financing Explanation

Cash from financing contains six items:

1. Issuance of Stock:
A company may raise cash from issuing new shares. Issuance of stock represents the cash inflow from offering common stock, which is the additional capital contribution to the entity during the period.

Takeda Pharmaceutical Co's issuance of stock for the three months ended in Mar. 2024 was $0 Mil.

2. Repurchase of Stock:
A company may raise cash from issuing new shares. It can also use cash to buy back shares. Repurchase of stock represents the cash outflow to reacquire common stock during the period.

Takeda Pharmaceutical Co's repurchase of stock for the three months ended in Mar. 2024 was $0 Mil.

3. Net Issuance of Debt:
Net issuance of debt is the cash a company received or spent through debt related activities such as debt issuance or debt repayment. If a company pays down its debt during the period, this number will be negative. If a company issued more debt, it receives cash and this number is positive.

Takeda Pharmaceutical Co's net issuance of debt for the three months ended in Mar. 2024 was $-95 Mil. Takeda Pharmaceutical Co spent $95 Mil paying down its debt.

4. Net Issuance of Preferred Stock:
A company may raise cash from issuing new preferred shares. It can also use cash to buy back preferred shares. If this number is positive, it means that the company has received more cash from issuing preferred shares than it has paid to buy back preferred shares. If this number is negative, it means that company has paid more cash to buy back preferred shares than it has received for issuing preferred shares.

Takeda Pharmaceutical Co's net issuance of preferred for the three months ended in Mar. 2024 was $0 Mil. Takeda Pharmaceutical Co paid $0 Mil more to buy back preferred shares than it received from issuing preferred shares.

5. Cash Flow for Dividends:
Cash flow for dividends refers to the payment of cash to shareholders as dividends when the company generates income.

Takeda Pharmaceutical Co's cash flow for dividends for the three months ended in Mar. 2024 was $-61 Mil. Takeda Pharmaceutical Co spent $61 Mil paying cash dividends to shareholders.

6. Other Financing:
Money spent or earned by company from other financial activities.

Takeda Pharmaceutical Co's other financing for the three months ended in Mar. 2024 was $-232 Mil. Takeda Pharmaceutical Co spent $232 Mil on other financial activities.


Takeda Pharmaceutical Co Cash Flow from Financing Related Terms

Thank you for viewing the detailed overview of Takeda Pharmaceutical Co's Cash Flow from Financing provided by GuruFocus.com. Please click on the following links to see related term pages.


Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Business Description

Address
1-1, Nihonbashi-Honcho 2-Chome, Chuo-ku, Tokyo, JPN, 103-8668
Takeda Pharmaceutical is Japan's largest pharmaceutical company, with revenue of JPY 4 trillion in fiscal 2022. The company's five core therapeutic areas are oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies, which account for more than 80% of revenue. Its geographic footprint is well diversified, with 50% derived from the U.S., 20% from Japan, 20% from Europe and Canada.

Takeda Pharmaceutical Co (Takeda Pharmaceutical Co) Headlines

From GuruFocus